Last reviewed · How we verify
NCT04172961
Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days
Phase 4 trial testing nanomicellular cyclosporine 0.09% in Dry Eye in 100 participants. Status unknown.
1 December 2022
Quick facts
| Lead sponsor | Toyos Clinic |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 February 2020 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- nanomicellular cyclosporine 0.09% — full drug profile →
- Lifitegrast (LIFITEGRAST) — full drug profile →
Conditions studied
- Dry Eye — all drugs for Dry Eye →
Sponsor
Toyos Clinic
Who can join
Adults 18 to 85, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be a randomized, double-blind prospective in 3 clinical sites to compare the efficacy of two currently approved topical ophthalmic drops in the clearing central corneal staining in 90 days prior to elective cataract or LASIK surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dry eye syndrome: comprehensive etiologies and recent clinical trials.
Huang R, Su C, Fang L, Lu J, et al · · 2022 · cited 52× · PMID 35678897 · DOI 10.1007/s10792-022-02320-7
Verify or expand the search:
- PubMed search for NCT04172961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye
Currently open trials in the same condition.
- NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
- NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
- NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting
Other Toyos Clinic trials
Trials by the same sponsor.
- NCT06964269 — Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune D · Phase 4 · recruiting
- NCT06947850 — DOMPE -MT Neurotrophic Keratitis · Phase 4 · active not recruiting
- NCT03286166 — Single Center, Prospective, Randomized, Controlled, Non-significant Risk · withdrawn
- NCT03862053 — Manuka Eye Droops for Treatment of Allergy · Phase 4 · withdrawn
- NCT03788486 — Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04172961 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Toyos Clinic
- Last refreshed: 20 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04172961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing